Dr. Weisman discusses the future of Alzheimer’s on NBC 10

Abington Neurological Associates’ Dr. David Weisman sat down with NBC10’s Keith Jones to discuss the effects of Alzheimer’s Disease and the NOBLE clinical trial.

It’s a slow disease, and it’s one that doesn’t have a lot of what we call biomarkers. So, for instance, cancer: you take a few people with cancer, and if you have a medication that shrinks the tumors on scans, then you can scale that up easily. Alzheimer’s is much harder and it’s much slower. It’s such a slow disease that we need dozens and hundreds of people over many years to see an effect. You can’t scale it up easily.

Watch the full interview on nbcphiladelphia.com.